The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis

Biology of Reproduction

Volumn 87, Issue 6, 2012, Pages

  Tal, Reshef ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Angiotensin II receptor type I autoimmune antibody; Endothelin ,1 hypoxia, hypoxia inducible factor 1 (HIF1A; HIF 1a); Preeclampsia; Soluble endoglin; Solublefms like tyrosine kinase 1 (sFLT 1)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; AGTR1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; VASCULOTROPIN RECEPTOR 1;

ALTITUDE; HUMAN; HYPERTENSION; HYPOXIA; NONHUMAN; PATHOGENESIS; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHORT SURVEY; TROPHOBLAST; ANIMAL; BIOSYNTHESIS; BLOOD; CELL HYPOXIA; CHEMISTRY; DRUG ANTAGONISM; FEMALE; IMMUNOLOGY; METABOLISM; PLACENTA; PREGNANCY; REVIEW; SOLUBILITY;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; CELL HYPOXIA; ENDOTHELIN-1; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, CELL SURFACE; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84877666331     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.102723     Document Type: Short Survey

References (104)

1. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 2009; 76(8):831-837.
2. Baker PN, Krasnow J, Roberts JM, Yeo KT. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 1995; 86(5):815-821.
3. Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, Charnock-Jones DS, Morris NH, Smith SK. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by preeclampsia. Eur J Clin Invest 1996; 26(12):1182-1185.
4. Hunter A, Aitkenhead M, Caldwell C, McCracken G, Wilson D, McClure N. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 2000; 36(6): 965-969.
5. Bosio PM, Wheeler T, Anthony F, Conroy R, O'Herlihy C, McKenna P. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 2001; 184(2):146-152.
6. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in preeclampsia. Br J Obstet Gynaecol 1997; 104(2):223-228.
7. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterizes pregnancies complicated by preeclampsia. Br J Obstet Gynaecol 1999; 106(10): 1019-1022.
8. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183(6):1554-1557.
9. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188(1):177-182.
10. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59(6):1540-1548.
11. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000; 95(3):353-357.
12. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350(7):672-683.
13. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111(5):649-658.
14. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293(1):77-85.
15. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23(1):101-111.
16. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102(12):1566-1574.
17. Thomas CP, Andrews JI, Raikwar NS, Kelley EA, Herse F, Dechend R, Golos TG, Liu KZ. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is upregulated in hypoxia and preeclampsia. J Clin Endocrinol Metab 2009; 94(7): 2524-2530.
18. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355(10):992-1005.
19. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12(6):642-649.
20. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21(1):9-23.
21. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22(11): 1021-1038.
22. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111(6):1403-1409.
23. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199(3):266.e1-266.e6.
24. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 2010; 5(10):e13263.
25. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49(4):818-824.
26. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Iams JD, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119(6):1234-1242.
27. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fmslike tyrosine kinase 1 and soluble endoglin in the prediction of preeclampsia: a systematic review and meta-analysis. BJOG 2012; 119(7):778-787.
28. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89(2):770-775.
29. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203(4):383.e1-383.e8.
30. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196(4):326.e1-326.e13.
31. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2008; 32(6): 732-739.
32. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for preeclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342:d1875.
33. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43(3):490-501.
34. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26(22):3709-3714.
35. Cross SN, Ratner E, Rutherford TJ, Schwartz PE, Norwitz ER. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012; 5(1):2-8.
36. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108(16):1933-1938.
37. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107(10): 1359-1365.
38. Brown MA, Zammit VC, Mitar DA, Whitworth JA. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992; 5(6 pt 1):366-371.
39. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens 2001; 14(11 pt 1):1154-1167.
40. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52(11):2682-2689.
41. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudanhausen JW, Haller H, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103(7):945-952.
42. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10(2):82-93.
43. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC III, Xia Y, Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110(12):1612-1619.
44. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14(8):855-862.
45. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55(2):386-393.
46. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007; 100(1):88-95.
47. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 2010; 121(3):436-444.
48. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18(7):945-953.
49. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352(6):558-569.
50. Langer B, Grima M, Coquard C, Bader AM, Schlaeder G, Imbs JL. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet Gynecol 1998; 91(2):196-202.
51. Dekker GA, Kraayenbrink AA, Zeeman GG, van Kamp GJ. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 1991; 40(3):215-220.
52. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991; 165(3):724-727.
53. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 2012; 26(4):236-241.
54. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37(2 pt 2):485-489.
55. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55(2):394-398.
56. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009; 54(4):905-909.
57. Lunell NO, Nylund LE, Lewander R, Sarby B. Uteroplacental blood flow in preeclampsia measurements with indium-113m and a computer-linked gamma camera. Clin Exp Hypertens B 1982; 1(1):105-117.
58. Roberts DJ, Post MD. The placenta in preeclampsia and intrauterine growth restriction. J Clin Pathol 2008; 61(12):1254-1260.
59. Zamudio S, Wu Y, Ietta F, Rolfo A, Cross A, Wheeler T, Post M, Illsley NP, Caniggia I. Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. Am J Pathol 2007; 170(6):2171-2179.
60. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005; 90(7):4299-4308.
61. Gilbert J, Dukes M, LaMarca B, Cockrell K, Babcock S, Granger J. Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. Am J Hypertens 2007; 20(6):686-691.
62. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71(10):977-984.
63. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeclamptic pregnancies. Br J Obstet Gynaecol 1994; 101(8): 669-674.
64. Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009; 53(2):399-403.
65. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50(6): 1142-1147.
66. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension 2008; 52(6):1168-1172.
67. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291(4):R1085-R1093.
68. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25(10): 763-769.
69. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294(5545):1337-1340.
70. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107(1):43-54.
71. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20(18): 5197-5206.
72. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292(5516):468-472.
73. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295(5556):858-861.
74. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15(20):2675-2686.
75. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105(5):577-587.
76. Rajakumar A, Conrad KP. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod 2000; 63(2):559-569.
77. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103(12): 1641-1650.
78. Caniggia I, Winter JL. Adriana and Luisa Castellucci Award Lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and preeclamptic pregnancies-a review. Placenta 2002; 23(suppl A):S47-S57.
79. Ashur-Fabian O, Yerushalmi GM, Mazaki-Tovi S, Steinberg DM, Goldshtein I, Yackobovitch-Gavan M, Schiff E, Amariglio N, Rechavi G. Cell-free expression of hif1alpha and p21 in maternal peripheral blood as a marker for preeclampsia and fetal growth restriction. PLoS ONE 2012; 7(5):e37273.
80. Zamudio S. High-altitude hypoxia and preeclampsia. Front Biosci 2007; 12:2967-2977.
81. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/ CBP. J Biol Chem 2001; 276(16):12645-12653.
82. Minchenko A, Caro J. Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive element. Mol Cell Biochem 2000; 208(1-2):53-62.
83. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277(46):43799-43808.
84. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172(1):77-85.
85. Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbard E, et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther 2008; 16(12):1927-1936.
86. Tal R, Shaish A, Barshack I, Polak-Charcon S, Afek A, Volkov A, Feldman B, Avivi C, Harats D. Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol 2010; 177(6):2950-2962.
87. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2-methoxyestradiol is associated with preeclampsia. Nature 2008; 453(7198):1117-1121.
88. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 2010; 176(2):710-720.
89. Palmer K, Saglam B, Whitehead C, Stock O, Lappas M, Tong S. Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. Am J Pathol 2011; 178(6):2484-2488.
90. Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catechol-Omethyl transferase activity in the human term placenta. Am J Perinatol 1988; 5(2):121-127.
91. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60(2):141-151.
92. Sata F, Yamada H, Suzuki K, Saijo Y, Yamada T, Minakami H, Kishi R. Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics 2006; 16(11): 775-781.
93. Abdul-Hafez A, Shu R, Uhal BD. JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts. FASEB J 2009; 23(6):1655-1662.
94. Zhang R, Wu Y, Zhao M, Liu C, Zhou L, Shen S, Liao S, Yang K, Li Q, Wan H. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2009; 297(4):L631-L640.
95. Sanchez-Lopez E, Lopez AF, Esteban V, Yague S, Egido J, Ruiz-Ortega M, Alvarez-Arroyo MV. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal 2005; 7(9-10): 1275-1284.
96. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H, Brewer J, Roberts L, Hubel CA, Herse F, Hering L, Qadri F, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58(1):77-84.
97. Gould PS, Gu M, Liao J, Ahmad S, Cudmore MJ, Ahmed A, Vatish M. Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. Hypertension 2010; 56(1):172-178.
98. Imperatore A, Rolfo A, Petraglia F, Challis JR, Caniggia I. Hypoxia and preeclampsia: increased expression of urocortin 2 and urocortin 3. Reprod Sci 2010; 17(9):833-843.
99. Rolfo A, Garcia J, Todros T, Post M, Caniggia I. The double life of MULE in preeclamptic and IUGR placentae. Cell Death Dis 2012; 3: e305.
100. Rajakumar A, Michael HM, Daftary A, Jeyabalan A, Gilmour C, Conrad KP. Proteasomal activity in placentas from women with preeclampsia and intrauterine growth restriction: implications for expression of HIFalpha proteins. Placenta 2008; 29(3):290-299.
101. Rajakumar A, Doty K, Daftary A, Markovic N, Conrad KP. Expression of von Hippel-Lindau (pVHL) protein in placentae from normal pregnant women and women with preeclampsia. Placenta 2006; 27(4-5):411-421.
102. Rolfo A, Many A, Racano A, Tal R, Tagliaferro A, Ietta F, Wang J, Post M, Caniggia I. Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies. PLoS ONE 2010; 5(10): e13288.
103. Kim SY, Park SY, Lim JH, Lee BY, Yang JH, Ryu HM. Hypoxia inducible factor-1alpha (HIF-1alpha) gene polymorphisms in Korean patients with preeclampsia. J Endocrinol Invest 2012; 35(7):670-675.
104. Nava-Salazar S, Sanchez-Rodriguez EN, Mendoza-Rodriguez CA, Moran C, Romero-Arauz JF, Cerbon MA. Polymorphisms in the hypoxia-inducible factor 1 alpha gene in Mexican patients with preeclampsia: a case-control study. BMC Res Notes 2011; 4:68.